Article

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of “high value, cost-conscious, cost-aware” care. This ensures that only appropriate treatments are administered to patients with cancer.

Dr Sugarbaker suggests to the fellow panelists that the majority of NSCLC patients are not candidates for surgery because they are diagnosed too late for a procedure. Early detection would save a lot of money.

“The issue of imaging and early detection certainly resonates with payers, including myself, and not only economic but ethical considerations,” says Dr Peskin. He adds that while people gravitate toward the terms “targeted” and “precision,” one must verify that those treatments are used by clinicians and oncologists judicially.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo